Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

Quest Diagnostics (DGX) stock climbed slightly today, gaining just above 0% after a relatively quiet session. Investors seem to be weighing recent performance, as shares are up 17% year-to-date and ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings ...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive ...

Quest Diagnostics is launching a new pharmacogenomics program designed to decode patients’ DNA to predict how they will respond to certain therapies and doses. The company said its test will span ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

One of the top diagnostics specialists on the market published quarterly and full-year results. It not only scored a double beat on analyst projections, but its revenue guidance came out ahead as well ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...